Possible relationships between plasma carbamazepine-10,11-epoxide levels and antimanic efficacy and side effects in patients with schizoaffective disorde

Reiji Yoshimura; Jun Nakamura; Seiji Eto; Nobuhisa Ueda

doi:10.1002/1099-1077(200006)15:4<237::AID-HUP160>3.0.CO;2-5

Possible relationships between plasma carbamazepine-10,11-epoxide levels and antimanic efficacy and side effects in patients with schizoaffective disorde

Hum Psychopharmacol. 2000 Jun;15(4):237-240. doi: 10.1002/1099-1077(200006)15:4<237::AID-HUP160>3.0.CO;2-5.

Authors

Reiji Yoshimura¹, Jun Nakamura, Seiji Eto, Nobuhisa Ueda

Affiliation

¹ Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan.

PMID: 12404318
DOI: 10.1002/1099-1077(200006)15:4<237::AID-HUP160>3.0.CO;2-5

Abstract

We examined the relationships of plasma levels of carbamazepine (CBZ) and its two major metabolites, carbamazepine-10,11-epoxide (CBZ-E) and carbamazepine-10,11-diol (CBZ-D), with antimanic efficacy and side effects in patients with schizoaffective disorder. Positive relationships were found among plasma concentrations of CBZ-E and the degree of clinical improvement and side effects, whereas neither plasma CBZ nor CBZ-D levels were correlated with the degree of clinical improvement or side effects. Copyright 2000 John Wiley & Sons, Ltd.